CA3111862A1 - Anti-lilrb2 antibodies and methods of use thereof - Google Patents

Anti-lilrb2 antibodies and methods of use thereof Download PDF

Info

Publication number
CA3111862A1
CA3111862A1 CA3111862A CA3111862A CA3111862A1 CA 3111862 A1 CA3111862 A1 CA 3111862A1 CA 3111862 A CA3111862 A CA 3111862A CA 3111862 A CA3111862 A CA 3111862A CA 3111862 A1 CA3111862 A1 CA 3111862A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3111862A
Other languages
English (en)
French (fr)
Inventor
Shu-Hsia Chen
Ping-Ying Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Methodist Hospital
Original Assignee
Icahn School of Medicine at Mount Sinai
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, Methodist Hospital filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA3111862A1 publication Critical patent/CA3111862A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3111862A 2018-09-17 2019-09-17 Anti-lilrb2 antibodies and methods of use thereof Pending CA3111862A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732299P 2018-09-17 2018-09-17
US201862732334P 2018-09-17 2018-09-17
US62/732,334 2018-09-17
US62/732,299 2018-09-17
PCT/US2019/051529 WO2020061059A1 (en) 2018-09-17 2019-09-17 Anti-lilrb2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3111862A1 true CA3111862A1 (en) 2020-03-26

Family

ID=69888746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3111862A Pending CA3111862A1 (en) 2018-09-17 2019-09-17 Anti-lilrb2 antibodies and methods of use thereof

Country Status (8)

Country Link
US (1) US12157768B2 (enExample)
EP (1) EP3852805A4 (enExample)
JP (1) JP2022501428A (enExample)
KR (1) KR20210108940A (enExample)
CN (1) CN113543804A (enExample)
AU (1) AU2019343131A1 (enExample)
CA (1) CA3111862A1 (enExample)
WO (1) WO2020061059A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121299117A (zh) * 2025-12-05 2026-01-09 中国农业科学院都市农业研究所 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
EP4076521A4 (en) * 2019-12-20 2024-01-24 Merck Sharp & Dohme LLC Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
CN115956089A (zh) 2020-05-04 2023-04-11 加利福尼亚大学董事会 抑制性抗enpp1抗体
CN116710132A (zh) * 2020-09-17 2023-09-05 默沙东有限责任公司 抗ilt4抗体或其与抗pd-1抗体的组合用于治疗癌症的给药方案
EP3981789A1 (en) 2020-10-12 2022-04-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Anti-lilrb antibodies and uses thereof
JP7854991B2 (ja) * 2020-10-21 2026-05-07 イミューン－オーエヌシー セラピューティクス，インコーポレーテッド 新規の抗ｌｉｌｒｂ２抗体および誘導体生成物
AU2022233201A1 (en) * 2021-03-11 2023-09-28 University Health Network Lilrb1 and lilrb2-binding molecules and uses therefor
WO2023279107A1 (en) * 2021-07-01 2023-01-05 Albert Einstein College Of Medicine Compositions and methods for inhibiting the expression of tmigd2
JP2025510232A (ja) * 2022-03-29 2025-04-14 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｉｌｔ３及びｃｄ３結合剤及びその使用方法
WO2023235706A1 (en) * 2022-05-31 2023-12-07 Ngm Biopharmaceuticals, Inc. Combination therapies using ilt-binding agents and pd-1 inhibitors
CN116082504B (zh) * 2022-06-28 2026-05-05 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN116333128B (zh) * 2022-06-28 2026-03-24 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
IL319145A (en) * 2022-08-22 2025-04-01 Antengene Biologics Ltd Novel anti-LILRB2 antibodies and their uses
WO2024051804A1 (zh) * 2022-09-08 2024-03-14 江苏恒瑞医药股份有限公司 抗ilt4抗体及其医药用途
KR20250090398A (ko) * 2022-09-28 2025-06-19 스팍스 바이오사이언스 리미티드 백혈구 면역글로불린 유사 수용체 하위 패밀리 b 구성원 2(lilrb2)에 결합하는 항체 및 그 용도
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
AU2023410277A1 (en) * 2022-12-23 2025-06-12 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
JP2026504928A (ja) * 2023-01-20 2026-02-10 ワシントン・ユニバーシティ Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法
CN116789826A (zh) * 2023-05-12 2023-09-22 南京师范大学 抗人lilrb2全人源单域抗体及其应用
CN119176874A (zh) * 2023-06-21 2024-12-24 康源博创生物科技(北京)有限公司 一种能够结合lilrb2的抗体或其抗原结合片段
WO2025128822A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Lilrb3 modulators and methods of use thereof
GB202319149D0 (en) * 2023-12-14 2024-01-31 Kbio Holdings Ltd Antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2912068B1 (en) * 2012-10-26 2019-06-19 Deutsches Rheuma-Forschungszentrum Berlin Bi-specific antibodies for cell-lineage-specific tnf-alpha neutralisation
JP6490574B2 (ja) * 2013-02-28 2019-03-27 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
EP2970373A1 (en) 2013-03-12 2016-01-20 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
CA2948871A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CA3218106A1 (en) * 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
US11359018B2 (en) * 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
TWI796329B (zh) * 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121299117A (zh) * 2025-12-05 2026-01-09 中国农业科学院都市农业研究所 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用
CN121299117B (zh) * 2025-12-05 2026-03-27 中国农业科学院都市农业研究所 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用

Also Published As

Publication number Publication date
US12157768B2 (en) 2024-12-03
CN113543804A (zh) 2021-10-22
AU2019343131A1 (en) 2021-04-29
EP3852805A1 (en) 2021-07-28
KR20210108940A (ko) 2021-09-03
WO2020061059A1 (en) 2020-03-26
US20220056128A1 (en) 2022-02-24
EP3852805A4 (en) 2022-06-15
JP2022501428A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
US12157768B2 (en) Anti-LILRB2 antibodies and methods of use thereof
US20240158538A1 (en) Vista antigen-binding molecules
US12435134B2 (en) Antagonists anti-CD7 antibodies
US11873346B2 (en) VISTA antigen-binding molecules
US11787858B2 (en) Anti-LILRB3 antibodies and methods of use thereof
US12514923B2 (en) Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9
AU2018301393B2 (en) Agonist antibodies that bind human CD137 and uses thereof
ES2961666T3 (es) Métodos para determinar la dosificación de células CAR-T
JP2022513778A (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
TW201607958A (zh) 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
CN107949571A (zh) 调控免疫反应的方法及抗体
US20210355220A1 (en) Antibodies specific to ctla-4 and uses thereof
US20260098093A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
WO2024035342A1 (en) B7-h3 antigen-binding molecules
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
JP2024542879A (ja) Ｐｄ－１およびｔｇｆ－ｂｒｉｉ結合ドメインを含む多重特異性結合部位
US20240101695A1 (en) Immunoglobulin e antibody compositions and methods of use
CN119546329A (zh) 用于通用肿瘤细胞杀伤的组合物和方法
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
WO2025075858A2 (en) ANTI-IL13Rα2 ANTIBODY COMPOSITIONS AND USES THEREOF
HK40015176A (zh) 抗lilrb3抗体及其使用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914